The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib

BACKGROUND: BRAF(V600E) mutation occurs in approximately 45% of papillary thyroid cancer (PTC) cases, and 25% of anaplastic thyroid cancer (ATC) cases. Vemurafenib/PLX4032, a selective BRAF inhibitor, suppresses extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Hao, Zhang, Jinna, Ning, Liang, Zhang, Honglai, Chen, Dong, Jiao, Xuelong, Zhang, Kejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2018
Materias:
Lab/In Vitro Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965018/
https://www.ncbi.nlm.nih.gov/pubmed/29737325
http://dx.doi.org/10.12659/MSM.910084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965018/
https://www.ncbi.nlm.nih.gov/pubmed/29737325
http://dx.doi.org/10.12659/MSM.910084

Ejemplares similares